Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-05

Zevra Therapeutics (ZVRA)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,821,924
R. LaDuane Clifton total, FY2025
Former Chief Financial Officer and Treasurerhighest-paid officer; CEO Neil McFarlane: $3,782,042
CEO (Neil McFarlane) pay percentile vs peers
CEO-to-median pay ratio
99.49%
Say-on-pay support, latest vote
Companies that benchmark against ZVRA
No companies currently name ZVRA as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
R. LaDuane Clifton$477,307$0$1,260,373$1,117,274$0$0$966,970$3,821,924
Former Chief Financial Officer and Treasurer
Neil McFarlane729,1670874,1251,748,250418,950011,5503,782,042
President, Chief Executive Officer and Director
Rahsaan Thompson466,66750,000272,680545,360178,600058,0671,571,374
Chief Legal Officer, Secretary and Compliance Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
R. LaDuane Clifton$3,821,924
Neil McFarlane3,782,042
Rahsaan Thompson1,571,374

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Neil McFarlanePSU466,667$4,181,336
Rahsaan ThompsonOption83,4867.17
Rahsaan ThompsonOption82,4239.06
Neil McFarlanePSU72,500649,600
Rahsaan ThompsonOption2,2508.26
Rahsaan ThompsonOption10,00042.56
Rahsaan ThompsonPSU133,3341,194,673
Rahsaan ThompsonOption3,125201.92
Neil McFarlanePSU112,5001,008,000
Rahsaan ThompsonOption4,68756.8
Neil McFarlanePSU100,000896,000
Rahsaan ThompsonOption4,68788
Rahsaan ThompsonOption68,0008.02
Rahsaan ThompsonPSU34,000304,640
Rahsaan ThompsonPSU20,000179,200
Neil McFarlaneOption300,0004.75
Rahsaan ThompsonOption10,0005.98
Rahsaan ThompsonOption459,7264.54
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program has been designed to motivate, reward, attract and retain high caliber management deemed essential to ensure our success. The program seeks to align executive compensation with our short- and long-term objectives, business strategy and financial performance. We intend that the total compensation of our NEOs reflects a 'pay for performance' compensation philosophy.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultantAlpine Rewards, LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0445,947,281234,753144,58299.49%Passed
20242024-05-1311,167,2159,888,153273,66153.04%Passed
20212021-06-176,845,7361,287,944159,45084.17%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0499.49%a
20242024-05-1353.04%b
20212021-06-1784.17%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Tamara A. FavoritoIndependent · Board Chair · Audit (Chair)$117,500$187,178$304,678
Alicia SecorIndependent · Audit · Compensation · Newly elected5,299259,579264,878
Thomas D. AndersonIndependent · Compensation (Chair) · Nominating and Corporate Governance65,000187,178252,178
Corey WattonIndependent · Audit · Compensation62,500187,178249,678
John B. BodeIndependent · Not standing for re-election59,735187,178246,913
Alvin Shih, M.DIndependent57,500187,178244,678
Douglas W. CalderIndependent · Compensation · Nominating and Corporate Governance (Chair)56,814187,178243,992
Wendy DixonIndependent50,516187,178237,694
Wendy Dixon, Ph.DIndependent · Not standing for re-election · Departed during FY50,516187,178237,694
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)22,500 / 15,000 / 12,500
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$525,380
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$525,380

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Zevra Therapeutics2025Neil McFarlane$729,167$874,125$1,748,250$418,950$3,782,042

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, R. LaDuane CliftonDEF 14A2026-04-200001434647-26-000025Section “Executive Compensation”. As printed: 3,821,924. Filing ↗machine: span 592019–592028
2Section 01, Neil McFarlaneDEF 14A2026-04-200001434647-26-000025Section “Executive Compensation”. As printed: 3,782,042. Filing ↗machine: span 580756–580765
3Section 01, Rahsaan ThompsonDEF 14A2026-04-200001434647-26-000025Section “Executive Compensation”. As printed: 1,571,374. Filing ↗machine: span 587532–587541
4Section 08, Tamara A. FavoritoDEF 14A2026-04-200001434647-26-000025Section “Director Compensation”. As printed: 304,678. Filing ↗machine: span 763596–763841
5Section 08, Alicia SecorDEF 14A2026-04-200001434647-26-000025Section “Director Compensation”. As printed: 264,878. Filing ↗machine: span 765980–766225
6Section 08, Thomas D. AndersonDEF 14A2026-04-200001434647-26-000025Section “Director Compensation”. As printed: 252,178. Filing ↗machine: span 754299–754544
7Section 08, Corey WattonDEF 14A2026-04-200001434647-26-000025Section “Director Compensation”. As printed: 249,678. Filing ↗machine: span 771007–771252
8Section 08, John B. BodeDEF 14A2026-04-200001434647-26-000025Section “Director Compensation”. As printed: 246,913. Filing ↗machine: span 756681–756926
9Section 08, Alvin Shih, M.DDEF 14A2026-04-200001434647-26-000025Section “Director Compensation”. As printed: 244,678. Filing ↗machine: span 768367–768612
10Section 08, Douglas W. CalderDEF 14A2026-04-200001434647-26-000025Section “Director Compensation”. As printed: 243,992. Filing ↗machine: span 758942–759187
11Section 08, Wendy DixonDEF 14A2026-04-200001434647-26-000025Section “Director Compensation”. As printed: 237,694. Filing ↗machine: span 761333–761578
12Section 08, Wendy Dixon, Ph.DDEF 14A2026-04-200001434647-26-000025Section “Director Compensation”. As printed: 237,694. Filing ↗machine: span 761333–761578
13Section 06, 2026 voteForm 8-K2026-06-050001434647-26-000041Item 5.07 · say-on-pay result. As reported: 99.49% (votes for as printed: 45,947,281). Filing ↗
14Section 06, 2024 voteForm 8-K2024-05-130001437749-24-016275Item 5.07 · say-on-pay result. As reported: 53.04% (votes for as printed: 11,167,215). Filing ↗
15Section 06, 2021 voteForm 8-K2021-06-240001437749-21-015558Item 5.07 · say-on-pay result. As reported: 84.17% (votes for as printed: 6,845,736). Filing ↗
16Section 09b board cost (computed)ComputedcomputedCash 525,380 + equity 0 + all other 0 = 525,380, summed across the director compensation table rows.machine: formula: Σ = 525,380
17Zevra Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-200001434647-26-000025CEO total compensation as printed in Zevra Therapeutics's own proxy. As printed: 3,782,042. Filing ↗machine: span 580756–580765